SCHEMBL3587616

SCHEMBL3587616

CNCc1ccc2c(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c(Cl)ccc2c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCB P05771 18/20 0.76
PRKCA P17252 14/20 0.76
PRKCD Q05655 11/20 0.76
PRKCH P24723 10/20 0.76
PRKCE Q02156 10/20 0.76
PRKCQ Q04759 10/20 0.76
CDK4 P11802 2/20 0.50
PRKACA P17612 2/20 0.50
PRKACG P22612 2/20 0.50
PRKACB P22694 2/20 0.50
CCND1 P24385 2/20 0.50
CDK2 P24941 2/20 0.50
PRKD3 O94806 1/20 0.50
CCNB2 O95067 1/20 0.50
CCNE2 O96020 1/20 0.50
ABL1 P00519 1/20 0.50
PRKCG P05129 1/20 0.50
CDK1 P06493 1/20 0.50
PIM1 P11309 1/20 0.50
CCNB1 P14635 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3541824 0.93 PRKCB (0.76) PRKCBPRKCAPRKCDPRKCHPRKCE
SCHEMBL3594020 0.86 PRKCB (1.00) PRKCBPRKCAPRKCDPRKCHPRKCE
SCHEMBL3599088 0.86 PRKCB (0.57) PRKCBPRKCAPRKCDPRKCHPRKCE
SCHEMBL3541190 0.84 PRKCB (0.60) PRKCBPRKCAPRKCDPRKCHPRKCE
SCHEMBL3543683 0.82 PRKCB (0.60) PRKCBPRKCAPRKCDPRKCHPRKCE
SCHEMBL3541633 0.80 PRKCB (1.00) PRKCBPRKCAPRKCDPRKCHPRKCE
SCHEMBL3545652 0.79 PRKCB (0.62) PRKCBPRKCAPRKCDPRKCHPRKCE
SCHEMBL14823686 0.75 PRKCB (0.53) PRKCBPRKCAPRKCDPRKCHPRKCE
SCHEMBL2834835 0.75 PRKCB (0.74) PRKCBPRKCAPRKCDPRKCHPRKCE
SCHEMBL3538925 0.74 PRKCA (1.00) PRKCBPRKCAPRKCDPRKCHPRKCE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691861-B2 Indolymaleimide derivatives NOVARTIS AG (CH) 2010-04-06 US claimed
US-20080234494-A1 Indolylmaleimide Derivatives NOVARTIS AG (CH) 2008-09-25 US claimed
EP-1709030-B1 INDOLYLMALEIMIDE DERIVATIVES NOVARTIS AG (CH) 2008-04-02 EP claimed
JP-2007518730-A 2007-07-12 JP claimed
EP-1709030-A1 INDOLYLMALEIMIDE DERIVATIVES Novartis AG (CH) 2006-10-11 EP claimed
WO-2005068454-A1 INDOLYLMALEIMIDE DERIVATIVES NOVARTIS AG (CH) 2005-07-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234494-A1 Indolylmaleimide Derivatives IDH3A, INMT, IDH2 PRKCB 3670/4885PRKCA 3950/4885PRKCD 3373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.